ClinicalTrials.gg
CompletedNCT02611830Updated May 25, 2022Results posted

Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis

A Phase 3 interventional study of Vedolizumab 300 mg IV and Placebo IV in Colitis, Ulcerative, sponsored by Takeda. Completed at 174 sites in 31 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-05-25.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
383
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
9th of 38
383 · median 110
Started
2015
with 2 others
Phase 3
14 of 38
3 open now
Registered
9th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 9th largest by enrollment, is one of 3 that started in 2015, is one of 14 in phase 3, and was the 9th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) maintenance treatment on clinical remission at Week 52 in participants with moderately to severely active ulcerative colitis (UC) who achieved clinical response following administration of vedolizumab intravenous (vedolizumab IV) induction therapy.

Read the detailed description

The drug being tested in this study is called vedolizumab subcutaneous (vedolizumab SC). Vedolizumab SC is being tested to treat people who have moderate to severely active ulcerative colitis. This study will look at clinical remission as well as mucosal healing, durable clinical response, durable clinical remission, and corticosteroid free remission in participants with UC who receive vedolizumab SC maintenance therapy after having achieved a clinical response to vedolizumab IV induction therapy.

The study enrolled 383 patients. All participants will enter into a 6-week Induction Phase where they will be administered open-label vedolizumab IV 300 mg via intravenous infusion (IV) at Week 0 (Day 1) and Week 2 (Day 15), and will then be assessed for a clinical response at Week 6. Participants who achieve a clinical response at Week 6 will be randomly assigned to one of the three treatment groups:

Vedolizumab SC 108 mg Q2W and Placebo IV Q8W Vedolizumab IV 300 mg Q8W and Placebo SC Q2W Placebo SC Q2W and Placebo IV Q8W

Participants who do not achieve a clinical response at Week 6 will not be randomized in to the Maintenance Period, and will receive a third infusion of vedolizumab IV 300 mg at Week 6.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 71 weeks (up to 4 weeks of screening, 52 weeks of treatment and 18 weeks of safety follow-up). Participants will make multiple visits to the clinic, plus a final visit 18 weeks after last dose of study drug for a follow-up assessment. Participants will also participate in a long-term safety follow-up, by phone, at 6 months after the last dose of study drug.

After the Week 52 assessments, participants meeting protocol-defined criteria were eligible to enroll in Study MLN0002SC-3030 (NCT02620046; Long-term Safety) to receive open-label vedolizumab treatment. Participants who withdrew early (prior to Week 52) due to sustained nonresponse, disease worsening, or the need for rescue medications may also have been eligible for Study MLN0002SC-3030. Participants who did not enroll into Study MLN0002SC-3030 were to complete a final on-study safety assessment at Week 68 (or final safety visit 18 weeks after the last dose) in the Maintenance Phase of Study MLN0002SC-3027.

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of ulcerative colitis (UC) established at least 6 months prior to screening, by clinical and endoscopic evidence and corroborated by a histopathology report.
  2. Moderately to severely active UC as determined by a complete Mayo score of 6-12 (with an endoscopic subscore ≥2)
  3. Evidence of UC extending proximal to the rectum (≥15 cm of involved colon).
  4. Inadequate response with, loss of response to, or intolerance to , immunomodulators, or Tumor Necrosis Factor-alpha (TNF-α) antagonists

Exclusion criteria

Exclusion Criteria:

  1. Evidence of abdominal abscess or toxic megacolon at the initial Screening Visit.
  2. Extensive colonic resection, subtotal or total colectomy.
  3. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
  4. Prior exposure to or approved non-biologic therapies (eg, cyclosporine, tacrolimus, thalidomide, methotrexate or tofacitinib) for the treatment of underlying disease within 30 days or 5 half-lives of screening (whichever is longer).
  5. Prior exposure to any investigational or approved biologic or biosimilar agent within 60 days or 5 half-lives of screening (whichever is longer).
  6. Prior exposure to vedolizumab
  7. Surgical intervention for UC required at any time during the study.
  8. History or evidence of adenomatous colonic polyps that have not been removed or has a history or evidence of colonic mucosal dysplasia.
  9. Suspected or confirmed diagnosis of Crohn's entercolitis, indeterminate colitis, ischaemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis.
  10. Active infections
  11. Chronic virus (HBV) infection or chronic virus (HCV) infection, or tuberculosis (active or latent), identified congenital or acquired immunodeficiency. HBV immune participants (ie, being hepatitis B surface antigen [HBsAg] negative and hepatitis B antibody positive) may, however, be included.
  12. History of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, demyelinating or neurodegenerative disease.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
383 participants (actual)

Study arms

  • Experimental
    Maintenance Phase: Induction IV + Vedolizumab 108 mg SC

    Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab SC in maintenance phase. Vedolizumab SC, 108 mg, injection, Q2W and placebo-matching IV infusions, Q8W, starting at Week 6 up to approximately Week 50.

    Drug: Vedolizumab 300 mg IV · Drug: Placebo IV · Drug: Vedolizumab 108 mg SC

  • Experimental
    Maintenance Phase: Induction IV + Vedolizumab 300 mg IV

    Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab IV in maintenance phase. Vedolizumab 300 mg, IV infusion, Q8W and placebo-matching SC injection, Q2W starting at Week 6 up to approximately Week 50.

    Drug: Vedolizumab 300 mg IV · Drug: Placebo SC

  • Experimental
    Maintenance Phase: Induction IV + Placebo

    Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive placebo in maintenance phase. Placebo-matching subcutaneous (SC) injections, once every 2 weeks (Q2W) and placebo-matching IV infusions, once every 8 weeks (Q8W) starting at Week 6 up to approximately Week 50.

    Drug: Vedolizumab 300 mg IV · Drug: Placebo IV · Drug: Placebo SC

Interventions

  • Vedolizumab intravenous infusion

  • DrugPlacebo IV

    Vedolizumab intravenous infusion placebo

  • Vedolizumab subcutaneous injection

  • DrugPlacebo SC

    Vedolizumab subcutaneous injection placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Remission at Week 52

    Clinical remission is defined as a complete Mayo score ≤ 2 points and no individual subscore \> 1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Achieving Mucosal Healing at Week 52

    Mucosal healing is defined as Mayo endoscopic subscore ≤1 point. The findings on endoscopy scale ranges from 0 to 3, where 0=normal or inactive disease 1=mild disease (erythema, decreased vascular pattern, mild friability) 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions) 3=severe disease (spontaneous bleeding, ulceration).

    Time frame: Week 52

  2. Percentage of Participants Achieving Durable Clinical Response at Week 6 and Week 52

    Durable clinical response is defined as clinical response at both Weeks 6 and 52, where clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Time frame: Baseline, Weeks 6 and 52

  3. Percentage of Participants Achieving Durable Clinical Remission at Week 6 and Week 52

    Durable clinical remission is defined as clinical remission at both Weeks 6 and 52. Clinical remission is defined as a complete Mayo score of less than or equal to (≤) 2 points and no individual subscore greater than (\>) 1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Time frame: Weeks 6 and 52

  4. Percentage of Participants Achieving Corticosteroid-free Remission at Week 52

    Corticosteroid-free remission is defined as participants using oral corticosteroids at Baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52. Clinical remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

    Time frame: Week 52

07

Results

Posted Jan 23, 2020

Participant flow

Participants took part in the study at one hundred forty-one investigative sites in North America, South America, Western/Northern Europe, Central Europe, Eastern Europe and Africa/Asia/Australia from 18-Dec-2015 to 21-Aug-2018.

OL Induction Phase
Participant flow — OL Induction Phase
MilestoneOpen-Label Induction Phase: Vedolizumab 300 mg IVMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IV
Started383000
Completed353000
Not completed30000
Withdrew: Pretreatment event/adverse event9000
Withdrew: Significant protocol deviation4000
Withdrew: Voluntary withdrawal5000
Withdrew: Lack of efficacy9000
Withdrew: Reason not specified3000
Maintenance Phase
Participant flow — Maintenance Phase
MilestoneOpen-Label Induction Phase: Vedolizumab 300 mg IVMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IV
Started05610654
Completed0207539
Not completed0363115
Withdrew: Lack of efficacy029186
Withdrew: Pretreatment event/adverse event0552
Withdrew: Significant protocol deviation0011
Withdrew: Lost to follow-up0001
Withdrew: Voluntary withdrawal0125
Withdrew: Pregnancy0010
Withdrew: Reason not specified0140

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Remission at Week 52

Clinical remission is defined as a complete Mayo score ≤ 2 points and no individual subscore \> 1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission at Week 52
percentage of participantsMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IV
Percentage of Participants Achieving Clinical Remission at Week 5214.3 (6.4 to 26.2)46.2 (36.5 to 56.2)42.6 (29.2 to 56.8)
Statistical analysis
  • Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC · Cochran-Mantel-Haenszel · p = <0.001 (P-value was calculated by Cochran-Mantel-Haenszel (CMH) test stratified by randomization strata according to concomitant use of corticosteroids, clinical remission status at Week 6, and previous TNF-α antagonist failure/concomitant immunomodulator.) · Risk difference (rd): 32.3 · 95% CI 19.7 to 45.0
SecondaryPercentage of Participants Achieving Mucosal Healing at Week 52

Mucosal healing is defined as Mayo endoscopic subscore ≤1 point. The findings on endoscopy scale ranges from 0 to 3, where 0=normal or inactive disease 1=mild disease (erythema, decreased vascular pattern, mild friability) 2=moderate disease (marked erythema, lack of vascular pattern, friability, erosions) 3=severe disease (spontaneous bleeding, ulceration).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Mucosal Healing at Week 52
percentage of participantsMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IV
Percentage of Participants Achieving Mucosal Healing at Week 5221.4 (11.6 to 34.4)56.6 (46.6 to 66.2)53.7 (39.6 to 67.4)
Statistical analysis
  • Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC · Cochran-Mantel-Haenszel · p = <0.001 (P-value was calculated by CMH test stratified by randomization strata according to concomitant use of corticosteroids, clinical remission status at Week 6, and previous TNF-α antagonist failure/concomitant immunomodulator.) · Risk difference (rd): 35.7 · 95% CI 22.1 to 49.3
SecondaryPercentage of Participants Achieving Durable Clinical Response at Week 6 and Week 52

Durable clinical response is defined as clinical response at both Weeks 6 and 52, where clinical response is defined as a reduction in complete Mayo score of ≥3 points and ≥30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore of ≤1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

Time frame:
Baseline, Weeks 6 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Durable Clinical Response at Week 6 and Week 52
percentage of participantsMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IV
Percentage of Participants Achieving Durable Clinical Response at Week 6 and Week 5228.6 (17.3 to 42.2)64.2 (54.3 to 73.2)72.2 (58.4 to 83.5)
Statistical analysis
  • Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC · Cochran-Mantel-Haenszel · p = <0.001 (P-value was calculated by CMH test stratified by randomization strata according to concomitant use of corticosteroids, clinical remission status at Week 6, and previous TNF-α antagonist failure/concomitant immunomodulator.) · Risk difference (rd): 36.1 · 95% CI 21.2 to 50.9
SecondaryPercentage of Participants Achieving Durable Clinical Remission at Week 6 and Week 52

Durable clinical remission is defined as clinical remission at both Weeks 6 and 52. Clinical remission is defined as a complete Mayo score of less than or equal to (≤) 2 points and no individual subscore greater than (\>) 1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

Time frame:
Weeks 6 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Durable Clinical Remission at Week 6 and Week 52
percentage of participantsMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IV
Percentage of Participants Achieving Durable Clinical Remission at Week 6 and Week 525.4 (1.1 to 14.9)15.1 (8.9 to 23.4)16.7 (7.9 to 29.3)
Statistical analysis
  • Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC · Fisher Exact · p = 0.076 (P-value was calculated by Fisher's Exact Test.) · Risk difference (rd): 9.7 · 95% CI -6.6 to 25.7
SecondaryPercentage of Participants Achieving Corticosteroid-free Remission at Week 52

Corticosteroid-free remission is defined as participants using oral corticosteroids at Baseline (Week 0) who have discontinued oral corticosteroids and are in clinical remission at Week 52. Clinical remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \> 1 point. The Mayo score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 subscores: rectal bleeding, stool frequency, findings on endoscopy, and physician's global assessment. Each subscore is scored on a scale from 0 to 3 and the complete Mayo score ranges from 0 to 12 (higher scores indicate greater disease activity).

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Corticosteroid-free Remission at Week 52
percentage of participantsMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IV
Percentage of Participants Achieving Corticosteroid-free Remission at Week 528.3 (1.0 to 27.0)28.9 (16.4 to 44.3)28.6 (11.3 to 52.2)
Statistical analysis
  • Maintenance Phase: Induction IV + Placebo vs Maintenance Phase: Induction IV + Vedolizumab 108 mg SC · Fisher Exact · p = 0.067 (P-value was calculated by Fisher's Exact Test.) · Risk difference (rd): 20.6 · 95% CI -4.5 to 43.7

Adverse events

Collected over From first dose up to 18 weeks post last dose of study drug (Up to approximately 68 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vedolizumab IV 300 mg, Induction Phase Only0/167 (0%)17/167 (10.2%)34/167 (20.4%)
Maintenance Phase: Induction IV + Placebo0/56 (0%)6/56 (10.7%)31/56 (55.4%)
Maintenance Phase: Induction IV + Vedolizumab 108 mg SC0/106 (0%)10/106 (9.4%)42/106 (39.6%)
Maintenance Phase: Induction IV + Vedolizumab 300 mg IV0/54 (0%)7/54 (13%)31/54 (57.4%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventVedolizumab IV 300 mg, Induction Phase OnlyMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IV
Colitis ulcerativeGastrointestinal disorders12/1675/563/1061/54
AnaemiaBlood and lymphatic system disorders2/1671/562/1060/54
CholelithiasisHepatobiliary disorders0/1670/560/1061/54
Craniocerebral injuryInjury, poisoning and procedural complications0/1670/560/1061/54
Clavicle fractureInjury, poisoning and procedural complications0/1670/560/1061/54
Scapula fractureInjury, poisoning and procedural complications0/1670/560/1061/54
Ligament ruptureInjury, poisoning and procedural complications0/1670/560/1061/54
Road traffic accidentInjury, poisoning and procedural complications0/1670/560/1061/54
Lumbar vertebral fractureInjury, poisoning and procedural complications0/1670/560/1061/54
Rib fractureInjury, poisoning and procedural complications0/1670/560/1061/54
Most frequent other events
Showing 10 of 12
Most frequent other events
EventVedolizumab IV 300 mg, Induction Phase OnlyMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IV
Colitis ulcerativeGastrointestinal disorders7/16714/5612/1065/54
NasopharyngitisInfections and infestations4/16711/5611/10610/54
HeadacheNervous system disorders5/1676/569/1060/54
Upper respiratory tract infectionInfections and infestations3/1671/5610/1062/54
AnaemiaBlood and lymphatic system disorders9/1672/565/1065/54
Urinary tract infectionInfections and infestations5/1672/560/1064/54
ArthralgiaMusculoskeletal and connective tissue disorders4/1671/566/1064/54
Alanine aminotransferase increasedInvestigations1/1670/561/1063/54
Blood creatine phosphokinase increasedInvestigations0/1670/561/1063/54
InsomniaPsychiatric disorders0/1670/561/1063/54

Baseline characteristics

The safety analysis set included all participants who received at least 1 dose of vedolizumab IV.

Age, Continuous
Age, Continuous(years)Vedolizumab IV 300 mg, Induction Phase OnlyMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IVTotal
Mean42.7 (18 to 79)39.4 (21 to 66)38.1 (18 to 69)41.6 (18 to 68)40.79 (18 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Vedolizumab IV 300 mg, Induction Phase OnlyMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IVTotal
Female79224123165
Male88346531218
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vedolizumab IV 300 mg, Induction Phase OnlyMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IVTotal
Hispanic or Latino01001
Non-Hispanic and Latino2467845
Not Collected143499946337
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vedolizumab IV 300 mg, Induction Phase OnlyMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IVTotal
American Indian or Alaska Native21003
Asian391314571
Black or African American10023
White125429247306
Region of Enrollment
Region of Enrollment(Participants)Vedolizumab IV 300 mg, Induction Phase OnlyMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IVTotal
Australia10214
Japan271010249
Korea, Republic Of1034320
Czech Republic2310419
Hungary222612
Poland3713351095
Serbia11013
Slovakia304310
Bosnia00202
Bulgaria31116
Croatia810110
Estonia20002
Israel20002
Romania40307
Russia1205320
Turkey12003
Ukraine1146223
Canada432211
United States2467845
Brazil40318
Mexico21003
Belgium02002
Denmark01001
Germany03317
Italy40239
Lithuania00415
Netherlands10001
Spain10001
United Kingdom10113
Height
Height(cm)Vedolizumab IV 300 mg, Induction Phase OnlyMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IVTotal
Mean169.3 (145 to 193)172.4 (147 to 194)171.9 (151 to 197)171.2 (152 to 196)170.7 (145 to 197)
Weight
Weight(kg)Vedolizumab IV 300 mg, Induction Phase OnlyMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IVTotal
Mean68.20 (37.0 to 150.2)73.96 (40.6 to 160.0)71.58 (44.0 to 131.0)76.95 (50.6 to 124.8)71.21 (37.0 to 160.0)
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Vedolizumab IV 300 mg, Induction Phase OnlyMaintenance Phase: Induction IV + PlaceboMaintenance Phase: Induction IV + Vedolizumab 108 mg SCMaintenance Phase: Induction IV + Vedolizumab 300 mg IVTotal
Mean23.65 (15.1 to 40.3)24.66 (14.1 to 51.1)24.07 (17.0 to 41.0)26.21 (16.3 to 35.3)24.28 (14.1 to 51.1)

13 further baseline measures are reported on the registry.

08

Study locations

174 sites
  • Arkansas Primary Care Clinic, PA
    Little Rock, Arkansas 72204, United States
  • Rocky Mountain Clinical Research, LLC
    Wheat Ridge, Colorado 80033, United States
  • Middlesex Gastroenterology Associates
    Middletown, Connecticut 06457, United States
  • Nature Coast Clinical Research, LLC
    Inverness, Florida 34452, United States
  • Florida Center for Gastroenterology
    Largo, Florida 33777, United States
  • L & L Research Choices, Inc.
    Miami, Florida 33176, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • Gastroenterology Associates of Central Georgia
    Macon, Georgia 31201, United States
  • Atlanta Gastroenterology Specialists, PC
    Suwanee, Georgia 30024, United States
  • Cotton-O'Neil Clinical Research Center, Digestive Health
    Topeka, Kansas 66606, United States
  • Tri-State Gastroenterology Associates
    Crestview Hills, Kentucky 41017, United States
  • Research Concierge, LLC
    Owensboro, Kentucky 42303, United States
  • Gastroenterology Associates, LLC
    Baton Rouge, Louisiana 70809, United States
  • Metropolitan Gastroenterology Group, PC, Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Gastroenterology Associates of Western Michigan, P.L.C.
    Wyoming, Michigan 49519, United States
  • Ehrhardt Clinical Research, LLC
    Belton, Missouri 64012, United States
  • Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • Premier Medical Group of the Hudson Valley, PC
    Poughkeepsie, New York 12601, United States
  • Dayton Gastroenterology, Inc
    Dayton, Ohio 45415, United States
  • Options Health Research
    Tulsa, Oklahoma 74104, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Tyler Research Institute, LLC
    Tyler, Texas 75701, United States
  • Gastroenterology Associates of Tidewater
    Chesapeake, Virginia 23320, United States
  • Virginia Mason Seattle Main Clinic
    Seattle, Washington 98101, United States
  • Expertia S.A- Mautalen Salud e Investigacion
    Ciudad Autonoma Buenos Aires, C1128AAE, Argentina
  • Concord Repatriation General Hospital
    Concord, New South Wales 2139, Australia
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3181, Australia
  • Clinique Saint-Pierre
    Ottignies, 1340, Belgium
  • AZ Delta
    Roeselare, 8800, Belgium
  • University Clinical Centre of the Republic of Srpska
    Banja Luka, 78000, Bosnia and Herzegovina
  • Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda
    Goiania, Goias 74535-170, Brazil
  • HUCFF-UFRJ - Hospital Universitario Clementino Fraga Filho - Universidade Federal do Rio de Janeiro
    Rio de Janeiro, Rio Do Janeiro 21941-913, Brazil
  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
    Botucatu, Sao Paulo 18618-970, Brazil
  • Faculdade de Medicina do ABC
    Santo Andre, Sao Paulo 09060-650, Brazil
  • MHAT 'Avis Medica' OOD
    Pleven, 5800, Bulgaria
  • MHAT - Silistra AD
    Silistra, 7500, Bulgaria
  • MHAT "Hadzhi Dimitar", OOD
    Sliven, 8800, Bulgaria
  • Second MHAT - Sofia AD
    Sofia, 1202, Bulgaria
  • "City Clinic UMHAC" EOOD
    Sofia, 1407, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD
    Sofia, 1431, Bulgaria
  • UMHAT 'Tsaritsa Yoanna - ISUL', EAD
    Sofia, 1527, Bulgaria
  • Medical Center "Nov Rehabilitatsionen Tsentar", EOOD
    Stara Zagora, 6000, Bulgaria
  • London Health Science Centre
    London, Ontario N6A 5A5, Canada
  • LHSC - Victoria Hospital
    London, Ontario N6A 5W9, Canada
  • Toronto Digestive Disease Associates, Inc.
    Vaughan, Ontario L4L 4Y7, Canada
  • Clinical Hospital Centre Osijek
    Osijek, 31000, Croatia
  • Clinical Hospital Centre Rijeka
    Rijeka, 51000, Croatia
  • Clinical Hospital Centre Zagreb
    Zagreb, 10000, Croatia
  • Clinical Hospital Dubrava
    Zagreb, 10000, Croatia
  • Ccbr-Synarc A/S
    Brno, 60200, Czechia
  • Hepato-Gastroenterologie HK, s.r.o.
    Hradec Kralove, 500 12, Czechia
  • A-SHINE s.r.o.
    Plzen, 31200, Czechia
  • Ccbr-Synarc A/S
    Praha 3, 13000, Czechia
  • Axon Clinical, s.r.o.
    Praha 8, 182 00, Czechia
  • Odense Universitetshospital
    Odense C, 5000, Denmark
  • West Tallinn Central Hospital
    Tallinn, 10617, Estonia
  • Medizinische Hochschule Hannover
    Hannover, Niedersachsen 30625, Germany
  • EUGASTRO GmbH
    Leipzig, Sachsen 04103, Germany
  • Krankenhaus Waldfriede e. V.
    Berlin, 14163, Germany
  • Obudai Egeszsegugyi Centrum Kft.
    Budapest, 1036, Hungary
  • Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak
    Budapest, 1125, Hungary
  • Pest Megyei Flor Ferenc Korhaz
    Kistarcsa, 2143, Hungary
  • Karolina Korhaz-Rendelointezet
    Mosonmagyarovar, H-9200, Hungary
  • Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
    Szekesfehervar, 8000, Hungary
  • Tolna Megyei Balassa Janos Korhaz
    Szekszard, 7100, Hungary
  • Wolfson Medical Center
    Holon, 58100, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 52621, Israel
  • IRCCS Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Foggia 71013, Italy
  • Istituto Clinico Humanitas
    Rozzano, Milano 20089, Italy
  • I.R.C.C.S Policlinico San Donato
    San Donato Milanese, Milano 20097, Italy
  • Azienda Socio Sanitaria Territoriale Fatebenefratelli (Presidio Ospedale Sacco)
    Milano, 20157, Italy
  • Azienda Ospedaliera di Padova
    Padova, 35128, Italy
  • Azienda Ospedaliera San Camillo Forlanini
    Roma, 00152, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • Nagoya-shi, Aichi-Ken, Japan
  • Sakura-shi, Chiba-Ken, Japan
  • Matsuyama-shi, Ehime-Ken, Japan
  • Chikushino-shi, Fukuoka-Ken, Japan
  • Hiroshima-shi, Hiroshima-Ken, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Nishinomiya-shi, Hyogo-Ken, Japan
  • Takamatsu-shi, Kagawa-Ken, Japan
  • Kamakura-shi, Kanagawa-Ken, Japan
  • Okayama-shi, Okayama-Ken, Japan
  • Osaka-shi, Osaka-Fu, Japan
  • Saga-shi, Saga-Ken, Japan
  • Otsu-shi, Shiga-Ken, Japan
  • Hamamatsu-shi, Shizuoka-Ken, Japan
  • Bunkyo-ku, Tokyo-To, Japan
  • Minato-ku, Tokyo-To, Japan
  • Mitaka-shi, Tokyo-To, Japan
  • Shinjuku-ku, Tokyo-To, Japan
  • Wakayama-shi, Wakayama-Ken, Japan

Showing the first 100 of 174 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kobayashi T, Ito H, Ashida T, Yokoyama T, Nagahori M, Inaba T, Shikamura M, Yamaguchi T, Hori T, Pinton P, Watanabe M, Hibi T. Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis. Intest Res. 2021 Oct;19(4):448-460. doi: 10.5217/ir.2020.00026. Epub 2020 Aug 18. PubMed 32806876 ↗
  • Sandborn WJ, Baert F, Danese S, Krznaric Z, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020 Feb;158(3):562-572.e12. doi: 10.1053/j.gastro.2019.08.027. Epub 2019 Aug 28. PubMed 31470005 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in May 2018, 29 months.

Results were first posted in Jan 2020, 1 year 7 months after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 29 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2015
First posted
Nov 23, 2015
StartActual
Dec 18, 2015
Primary completionActual
May 30, 2018
CompletionActual
Aug 21, 2018
Results first posted
Jan 23, 2020
Last update
May 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02611830
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 23, 2015
Start date
Dec 18, 2015
Primary completion
May 30, 2018
Completion
Aug 21, 2018
Results posted
Jan 23, 2020
Last update
May 25, 2022

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion